CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands |
9 Months Ended |
Sep. 30, 2016 |
Sep. 30, 2015 |
| CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
| Net loss |
$ (187,303)
|
$ (157,781)
|
| Adjustments to reconcile net loss to cash flows from operating activities: |
|
|
| Depreciation and amortization |
69,605
|
63,815
|
| Share-based compensation expense |
74,613
|
74,473
|
| Deferred income taxes |
(12,545)
|
(35,073)
|
| Excess tax benefit from share-based compensation |
(5,118)
|
(32,817)
|
| Gain on the Gainesville Transaction |
|
(9,937)
|
| Change in the fair value of contingent consideration |
(3,100)
|
(2,700)
|
| Other non-cash charges |
1,901
|
|
| Other non-cash charges |
|
(520)
|
| Changes in assets and liabilities: |
|
|
| Receivables |
(21,960)
|
(1,955)
|
| Inventory, prepaid expenses and other assets |
(18,266)
|
13,542
|
| Accounts payable and accrued expenses |
26,833
|
46,291
|
| Deferred revenue |
(526)
|
(1,172)
|
| Other long-term liabilities |
4,506
|
1,059
|
| Cash flows used in operating activities |
(71,360)
|
(42,775)
|
| CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
| Additions of property, plant and equipment |
(33,787)
|
(36,729)
|
| Proceeds from the sale of equipment |
100
|
181
|
| Investment in Reset Therapeutics, Inc. |
(15,000)
|
|
| Net proceeds from the Gainesville Transaction |
|
50,267
|
| Purchases of investments |
(296,712)
|
(350,157)
|
| Sales and maturities of investments |
493,520
|
335,169
|
| Cash flows provided by (used in) investing activities |
148,121
|
(1,269)
|
| CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
| Proceeds from the issuance of ordinary shares under share-based compensation arrangements |
12,746
|
31,633
|
| Excess tax benefit from share-based compensation |
5,118
|
32,817
|
| Employee taxes paid related to net share settlement of equity awards |
(8,432)
|
(17,065)
|
| Principal payments of long-term debt |
(65,063)
|
(5,064)
|
| Cash flows (used in) provided by financing activities |
(55,631)
|
42,321
|
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
21,130
|
(1,723)
|
| CASH AND CASH EQUIVALENTS - Beginning of period |
181,109
|
224,064
|
| CASH AND CASH EQUIVALENTS - End of period |
202,239
|
222,341
|
| Non-cash investing and financing activities: |
|
|
| Purchased capital expenditures included in accounts payable and accrued expenses |
$ 3,642
|
2,409
|
| Fair value of warrants received as part of the Gainesville Transaction |
|
2,123
|
| Fair value of contingent consideration received as part of the Gainesville Transaction |
|
$ 57,600
|